For example, the iPAC may provide an important clue to the choice of drugs (e.g., aspirin or thienopyridines) for antiplatelet therapy (Mauri et al., 2014; Roe et al., 2012), the gold standard of the treatment and prevention of atherothrombosis (e.g., myocardial infarction, cerebral infarction), in that aspirin inhibits the formation of TXA2 whose stable analogue is U46619 while thienopyridines exert an antiplatelet effect by blocking the ADP receptor P2Y12. This evidence concerns the gene P2RY1 and cerebral infarction.